Telix Pharmaceuticals

Telix Pharmaceuticals Equity

The The Equity of Telix Pharmaceuticals (TLX.AX) as of Nov 19, 2026 is 415.38 M USD. In the previous year, The Equity was 352.94 M USD — a change of 17.69% (higher).

Equity

415.38 MUSD

YoY

17.69%

Last updated:

In 2025, Telix Pharmaceuticals's equity was 415.38 M USD, a 17.69% increase from the 352.94 M USD equity in the previous year.

The Telix Pharmaceuticals Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
52.90 M USD
Jan 1, 2019
70.08 M USD
Jan 1, 2020
79.02 M USD
Jan 1, 2021
2.16 M USD
Jan 1, 2022
51.88 M USD
Jan 1, 2023
102.65 M USD
Jan 1, 2024
352.94 M USD
Jan 1, 2025
415.38 M USD
The Telix Pharmaceuticals Equity history
YEAREquityYoY
415.38 MUSD+17.69%
352.94 MUSD+243.84%
102.65 MUSD+97.83%
51.88 MUSD+2,304.29%
2.16 MUSD-97.27%
79.02 MUSD+12.75%
70.08 MUSD+32.47%
52.90 MUSD+7.33%
49.29 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Telix Pharmaceuticals's Equity

Telix Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Telix Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Telix Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Telix Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Telix Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Telix Pharmaceuticals stock

The Equity of Telix Pharmaceuticals is 415.38 M USD in 2025.

The Equity of Telix Pharmaceuticals changed from 352.94 M USD to 415.38 M USD, representing a 17.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals